Dr. Maryam Rahman specializes in the neurosurgical care of patients with brain tumors. Her translational lab focuses on immunotherapy for brain tumors. Dr. Rahman has an interest in novel treatment techniques, including laser interstitial thermotherapy, fluorescence-guided surgery, immunotherapy/vaccine therapy and awake cortical mapping during surgery. She works in the Preston A. Wells Jr. Center for Brain Tumor Therapy.
Areas of Expertise (9)
Novel Treatment Techniques
Skull Based Tumors
Brain Tumor Surgery
Tumor Treating Fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastomaThe Journal of Clinical Investigation
Dongjiang Chen, et al.
Tumor Treating Fields (TTFields), an approved therapy for glioblastoma (GBM) and malignant mesothelioma, employ noninvasive application of low-intensity, intermediate-frequency, alternating electric fields to disrupt the mitotic spindle, leading to chromosome missegregation and apoptosis. Emerging evidence suggests that TTFields may also induce inflammation. However, the mechanism underlying this property and whether it can be harnessed therapeutically are unclear.
Glioma Immunotherapy: Advances and Challenges for Spinal Cord GliomasNeurospine
Clare Grady, et al.
Spinal cord gliomas are rare entities that often have limited surgical options. Immunotherapy has shown promise in intracranial gliomas with some research suggesting benefit for spinal cord gliomas. A focused review of immunotherapies that have been investigated in spinal cord gliomas was performed. The primary methods of immunotherapy investigated in spinal cord gliomas include immune checkpoint inhibitors, adoptive T-cell therapies, and vaccine strategies.
Slow-Cycling Cells in Glioblastoma: A Specific Population in the Cellular Mosaic of Cancer Stem CellsCancers
Changlin Yang, et al.
Glioblastoma (GBM) exhibits populations of cells that drive tumorigenesis, treatment resistance, and disease progression. Cells with such properties have been described to express specific surface and intracellular markers or exhibit specific functional states, including being slow-cycling or quiescent with the ability to generate proliferative progenies. In GBM, each of these cellular fractions was shown to harbor cardinal features of cancer stem cells (CSCs).